GGrantIndex
← Leaderboards

Laura Beretta

University Of Michigan At Ann Arbor

$16,561,253
Attributed
$18,319,699
Total exposure
10
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.7M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$29,589,703 · 11

By mechanism

P50$16,615,662 · 5
R01$12,936,041 · 5
P30$38,000 · 1

Top collaborators

Most similar at University Of Michigan At Ann Arbor

Same institution · by research overlap

Others in their field

Top investigators on “Primary Carcinoma Of The Liver Cells

Research focus

Primary Carcinoma Of The Liver CellsCirrhosisLiverUnited StatesDiagnosisCohortTumorEarly DiagnosisBaseHigh RiskTexasAffectBiological MarkersReportingIncidencePerformanceNonalcoholic SteatohepatitisPlasmaFibrosisSurveillance StrategyRisk FactorsProspectiveLiver CirrhosisSensitivity And Specificity

Grant awards (49)

Early Detection of Hepatocellular Carcinoma$663,299
R01 · FY2025 · CA · contact PI
Early Detection of Hepatocellular Carcinoma$630,129
R01 · FY2024 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma$2,206,679
P50 · FY2023 · CA · contact PI
Project 3: Non-invasive assessment of liver fibrosis stage and progression in obesity and diabetes: a Hispanic population study$1,023,762
P50 · FY2023 · CA · contact PI
Early Detection of Hepatocellular Carcinoma$649,953
R01 · FY2023 · CA · contact PI
Administrative Core$283,020
P50 · FY2023 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma$2,278,344
P50 · FY2022 · CA · contact PI
Early Detection of Hepatocellular Carcinoma$694,288
R01 · FY2022 · CA · contact PI
Project 3: Non-invasive assessment of liver fibrosis stage and progression in obesity and diabetes: a Hispanic population study$551,862
P50 · FY2022 · CA · contact PI
Genomics of HCC in the Hispanic population of Texas$353,471
R01 · FY2022 · CA · contact PI
Administrative Core$283,020
P50 · FY2022 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma$2,156,230
P50 · FY2021 · CA · contact PI
Project 3: Non-invasive assessment of liver fibrosis stage and progression in obesity and diabetes: a Hispanic population study$671,469
P50 · FY2021 · CA · contact PI
Genomics of HCC in the Hispanic population of Texas$360,685
R01 · FY2021 · CA · contact PI
Administrative Core$290,372
P50 · FY2021 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma$2,332,104
P50 · FY2020 · CA · contact PI
Administrative Core$818,458
P50 · FY2020 · CA · contact PI
Early Detection of Hepatocellular Carcinoma$644,190
R01 · FY2020 · CA · contact PI
Project 3: Non-invasive assessment of liver fibrosis stage and progression in obesity and diabetes: a Hispanic population study$575,175
P50 · FY2020 · CA · contact PI
Genomics of HCC in the Hispanic population of Texas$360,685
R01 · FY2020 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma$2,296,647
P50 · FY2019 · CA · contact PI
Early Detection of Hepatocellular Carcinoma$625,481
R01 · FY2019 · CA · contact PI
Project 3: Non-invasive assessment of liver fibrosis stage and progression in obesity and diabetes: a Hispanic population study$565,502
P50 · FY2019 · CA · contact PI
Genomics of HCC in the Hispanic population of Texas$349,864
R01 · FY2019 · CA · contact PI
Administrative Core$283,018
P50 · FY2019 · CA · contact PI
Early Detection of Hepatocellular Carcinoma$644,934
R01 · FY2018 · CA · contact PI
Genomics of HCC in the Hispanic population of Texas$390,463
R01 · FY2018 · CA · contact PI
Early Detection of Hepatocellular Carcinoma$611,462
R01 · FY2017 · CA · contact PI
Early Detection of Hepatocellular Carcinoma$645,417
R01 · FY2016 · CA · contact PI
Markers for HCV-related HCC: plasma profiling, targeted strategies and validation$302,718
R01 · FY2013 · CA · contact PI
Markers for HCV-related HCC: plasma profiling, targeted strategies and validation$354,244
R01 · FY2012 · CA · contact PI
Markers for HCV-related HCC: plasma profiling, targeted strategies and validation$354,244
R01 · FY2011 · CA · contact PI
Markers for HCV-related HCC: plasma profiling, targeted strategies and validation$365,200
R01 · FY2010 · CA · contact PI
Novel markers for HCV-related HCC$100,000
R01 · FY2010 · DK · contact PI
Markers for HCV-related HCC: plasma profiling, targeted strategies and validation$365,200
R01 · FY2009 · CA · contact PI
Novel markers for HCV-related HCC$34,521
R01 · FY2009 · DK · contact PI
Novel markers for HCV-related HCC$345,537
R01 · FY2008 · DK · contact PI
Novel markers for HCV-related HCC$353,069
R01 · FY2007 · DK · contact PI
Novel markers for HCV-related HCC$364,095
R01 · FY2006 · DK · contact PI
Role of 4E-BP1 and 4E-BP2 in Translational Control$337,869
R01 · FY2006 · AI · contact PI
Novel markers for HCV-related HCC$376,131
R01 · FY2005 · DK
Role of 4E-BP1 and 4E-BP2 in Translational Control$346,000
R01 · FY2005 · AI
Novel markers for HCV-related HCC$389,250
R01 · FY2004 · DK
Role of 4E-BP1 and 4E-BP2 in Translational Control$212,560
R01 · FY2004 · AI
Role of 4E-BP1 and 4E-BP2 in Translational Control$116,471
R01 · FY2004 · AI
Role of 4E-BP1 and 4E-BP2 in Translational Control$297,201
R01 · FY2003 · AI
Role of 4E-BP1 and 4E-BP2 in Translational Control$297,410
R01 · FY2002 · AI
PKR/ DIFFERENTIAL TRANSLATIONAL CONTROL IN LUPUS T CELLS$0
P30 · FY2002 · AR
PKR/ DIFFERENTIAL TRANSLATIONAL CONTROL IN LUPUS T CELLS$38,000
P30 · FY2001 · AR